[ad_1] Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton, Faculty of Medicine, School of Cancer Scie
[ad_1]
Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton, Faculty of Medicine, School of Cancer Sciences
Monoclonal antibodies (mAb) are now established as effective treatments for cancer, albeit with considerable potential for further improvement. The Antibody and Vaccine Group based in the Centre for Cancer Immunology in Southampton has a strong track-record in basic and translational immunology relating to developing therapeutic mAb for clinical examination.
We are currently running an extensive programme of research led by Profs Mark Cragg, Stephen Beers, Bjorn Frendeus and Dr Sean Lim to develop new and more effective antibody reagents for cancer patients. The current opportunity is for a research fellow to work on an exciting new project involving mAb capable of manipulating both T and myeloid cells to elicit powerful anti-tumour responses.
You will be motivated, educated in a relevant subject area and have practical laboratory experience of antibody biology and in vivo methodology.
The position is full-time and for 18 months in the first instance with the potential for a subsequent funding dependent upon progress.
Details about the Cancer Sciences and Centre for Cancer Immunology can be found at https://www.southampton.ac.uk/research/groups/cancer-sciences; https://www.southampton.ac.uk/research/institutes-centres/centre-for-cancer-immunology
*Applications will be considered from candidates who are working towards or nearing completion of a relevant PhD qualification. The title of Research Fellow will be applied upon completion of PhD. Prior to the qualification being awarded the title of Senior Research Assistant will be given.
Informal queries should be directed to Professor Mark Cragg (msc@soton.ac.uk)
Working at the University of Southampton:
Check out the staff benefits and why you should join us at The University of Southampton!
Further details:
[ad_2]
Source link
COMMENTS